STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Elaine Chen·
·1 min read
·
0 reactions
·
0 comments
·
23 views
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
Original article
STAT · Elaine Chen
Anonymous · no account needed
Discussion
0 commentsMore from STAT
STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claims
STAT·21
Opinion: MAHA is rewriting the vocabulary of American mental health care
STAT·19
STAT+: MDCalc is scoring the clinical calculators used by millions of doctors
STAT·18
Why affirming trans identities can be critical for suicide prevention counseling
STAT·20
WHO: Uganda is silent on updates following disclosure of Marburg outbreak
STAT·17
Cassidy grills Trump nominee on past vaccine comments in heated exchange
STAT·19